Greenrise Global Brands Inc (XCX) AI Stock Analysis

• Market Cap: C$258.28K
• Dividend Yield: N/A
• Average Volume (3M): 5.52K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.13
• Revenue Growth: N/A
• EPS Growth: -406.12%
• Country: CA
• Employees: 200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 51,655,370
• 10 Day Avg. Volume: 2,200
• 30 Day Avg. Volume: 5,516
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.44
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.01 ▲(0.00% Upside)

The score is driven primarily by very weak financial performance (recurring losses, negative equity, and a thin asset base relative to debt) and pressured/volatile cash generation. Valuation is also unattractive to assess due to negative earnings and no dividend data, while technicals cannot be evaluated with the indicators provided.

Positive Factors

Strategic Partnerships

Strategic partnerships enhance distribution capabilities and market penetration, potentially driving long-term revenue growth and brand recognition.

Product Innovation

Commitment to innovation in product development can lead to competitive advantages and meet diverse consumer needs, supporting long-term business sustainability.

Market Expansion

Diversified sales channels allow for broader market reach and customer base expansion, which can stabilize revenue streams over time.

Negative Factors

High Leverage

High leverage and negative equity pose significant financial risks, limiting operational flexibility and increasing vulnerability to economic downturns.

Negative Cash Flow

Negative cash flow challenges the company's ability to fund operations and invest in growth, potentially hindering long-term viability.

Revenue Generation Challenges

Lack of revenue generation highlights operational inefficiencies and market challenges, threatening the company's ability to sustain its business model.

Greenrise Global Brands Inc Business Overview & Revenue Model

Company Description

Greenrise Global Brands Inc., through its subsidiaries, operates as a pharmaceutical supplier of medical cannabis products to pharmacies in Germany. It offers a range of CBD products consisting of tinctures, sprays, oils, and skincare products through drugstores; and imports and sells EU-GMP medical and cosmetic cannabis products. The company was formerly known as AMP Alternative Medical Products Inc. and changed its name to Greenrise Global Brands Inc. in November 2021. Greenrise Global Brands Inc. is based in Vancouver, Canada.

How the Company Makes Money

Greenrise Global Brands Inc generates revenue primarily through the sale of its cannabis and hemp-based products. These products are sold through various channels, including direct-to-consumer sales, retail partnerships, and online platforms. The company may also engage in wholesale distribution to other businesses and maintain strategic partnerships with retailers and distributors to expand its market reach. Additional revenue streams can include licensing agreements for their proprietary strains or technologies. Collaboration with research institutions for product development can also contribute to its earnings, along with any ancillary services related to the cannabis industry.

Greenrise Global Brands Inc Financial Statement Overview

Summary

Financial health is very weak: revenue is minimal/inconsistent (including multiple years at $0), EBIT and net income are persistently negative (net loss -$1.08M in 2024), equity is negative (-$2.70M in 2024), and assets are extremely small ($93.5k) versus debt ($2.62M). Cash flow improved versus earlier heavy burn but reverted to negative in 2024 (FCF -$176k), keeping funding/solvency risk elevated.

Income Statement

Operating performance remains weak. Revenue is minimal/inconsistent (including multiple years at $0), and profitability is deeply negative: EBIT is losses every year (e.g., -$411k in 2024 vs. -$391k in 2023), with net income also solidly negative (-$1.08M in 2024; -$2.32M in 2022; -$3.64M in 2021). Margins are either negative (when revenue exists) or not meaningful due to near-zero sales, indicating the company has not yet reached a stable, scalable earnings base.

Balance Sheet

Balance sheet risk is high due to persistent negative equity (stockholders’ equity is -$2.70M in 2024, -$2.61M in 2023), which limits financial flexibility and makes leverage metrics less informative (debt-to-equity is negative because equity is negative). Total debt remains sizable ($2.62M in 2024) while total assets are very small ($93.5k in 2024, down sharply from $441.8k in 2023), highlighting a thin asset base relative to obligations and elevated solvency risk.

Cash Flow

Cash generation is volatile and generally pressured. Operating cash flow swung from positive in 2023 (+$199k) back to negative in 2024 (-$176k), and free cash flow followed the same pattern (-$176k in 2024 vs. +$199k in 2023). While free cash flow improved materially from the heavy burn in 2022 (-$1.08M), the return to negative cash flow in 2024 suggests funding needs may persist unless operating performance stabilizes.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	452.87K	105.20K
Gross Profit	0.00	0.00	0.00	0.00	43.32K	-153.00
EBITDA	-621.10K	-411.10K	0.00	-744.80K	-2.60M	-2.06M
Net Income	-804.55K	-1.08M	―	-2.32M	-3.64M	-2.11M
Balance Sheet
Total Assets	10.80K	93.53K	441.82K	1.25M	252.94K	371.56K
Cash, Cash Equivalents and Short-Term Investments	10.80K	13.53K	31.53K	-619.68K	27.45K	60.45K
Total Debt	2.71M	2.62M	2.80M	3.15M	1.90M	1.08M
Total Liabilities	2.86M	2.79M	3.06M	3.56M	2.26M	1.34M
Stockholders Equity	-3.00M	-2.70M	-2.61M	-2.32M	-2.00M	-972.61K
Cash Flow
Free Cash Flow	-158.52K	-176.13K	199.35K	-1.08M	-1.95M	-1.88M
Operating Cash Flow	-158.52K	-176.13K	199.35K	-1.08M	-1.89M	-1.83M
Investing Cash Flow	149.13K	60.40K	387.50K	-531.00K	-63.15K	45.43K
Financing Cash Flow	15.12K	97.73K	-534.73K	1.51M	1.92M	1.63M

Greenrise Global Brands Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRA	49 Neutral	C$420.72K	-0.31	―	―	―	―
XCX	41 Neutral	C$258.28K	-0.40	5.70%	―	―	-406.12%
CNTR	40 Underperform	C$289.94K	-1.05	―	―	―	―
LOWL	34 Underperform	C$272.55K	-0.01	―	―	―	―